De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Eurofins Scientific Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Eurofins Scientific has been growing earnings at an average annual rate of 8.2%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 8.8% per year. Eurofins Scientific's return on equity is 7.1%, and it has net margins of 4.8%.
Belangrijke informatie
8.2%
Groei van de winst
7.2%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 26.8% |
| Inkomstengroei | 8.8% |
| Rendement op eigen vermogen | 7.1% |
| Nettomarge | 4.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Earnings Tell The Story For Eurofins Scientific SE (EPA:ERF)
Aug 17
Results: Eurofins Scientific SE Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 27These 4 Measures Indicate That Eurofins Scientific (EPA:ERF) Is Using Debt Extensively
May 10We Discuss Why Eurofins Scientific SE's (EPA:ERF) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Apr 19Eurofins Scientific SE's (EPA:ERF) Price In Tune With Earnings
Apr 18Does Eurofins Scientific (EPA:ERF) Have A Healthy Balance Sheet?
Nov 10Eurofins Scientific SE's (EPA:ERF) Intrinsic Value Is Potentially 64% Above Its Share Price
Oct 23We Think Eurofins Scientific (EPA:ERF) Is Taking Some Risk With Its Debt
Aug 07Are Investors Undervaluing Eurofins Scientific SE (EPA:ERF) By 25%?
Jul 20We Think Eurofins Scientific (EPA:ERF) Can Stay On Top Of Its Debt
May 03Eurofins Scientific SE (EPA:ERF) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 11Estimating The Intrinsic Value Of Eurofins Scientific SE (EPA:ERF)
Jan 05Here's Why Eurofins Scientific (EPA:ERF) Can Manage Its Debt Responsibly
Dec 14An Intrinsic Calculation For Eurofins Scientific SE (EPA:ERF) Suggests It's 33% Undervalued
Oct 03Does Eurofins Scientific (EPA:ERF) Have A Healthy Balance Sheet?
Sep 06Eurofins Scientific (EPA:ERF) Is Increasing Its Dividend To €1.00
Jun 25Are Investors Undervaluing Eurofins Scientific SE (EPA:ERF) By 39%?
Jun 16Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Jun 01Should You Be Adding Eurofins Scientific (EPA:ERF) To Your Watchlist Today?
Apr 12These 4 Measures Indicate That Eurofins Scientific (EPA:ERF) Is Using Debt Safely
Feb 25Is Eurofins Scientific SE (EPA:ERF) Worth €114 Based On Its Intrinsic Value?
Nov 28Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Nov 14Here's Why I Think Eurofins Scientific (EPA:ERF) Might Deserve Your Attention Today
Sep 30Are Eurofins Scientific SE (EPA:ERF) Investors Paying Above The Intrinsic Value?
Aug 29We Think Eurofins Scientific (EPA:ERF) Can Manage Its Debt With Ease
Aug 15Do Eurofins Scientific's (EPA:ERF) Earnings Warrant Your Attention?
Jun 24Estimating The Fair Value Of Eurofins Scientific SE (EPA:ERF)
May 25Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Mar 31Does Eurofins Scientific (EPA:ERF) Deserve A Spot On Your Watchlist?
Mar 17Eurofins Scientific SE (EPA:ERF) Has Got What It Takes To Be An Attractive Dividend Stock
Mar 03Eurofins Scientific SE Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Mar 03Are Institutions Heavily Invested In Eurofins Scientific SE's (EPA:ERF) Shares?
Feb 15
Is Eurofins Scientific's (EPA:ERF) 117% Share Price Increase Well Justified?
Dec 28How Does Eurofins Scientific's (EPA:ERF) CEO Pay Compare With Company Performance?
Dec 14Eurofins Scientific (EPA:ERF) Is Growing Earnings But Are They A Good Guide?
Nov 30Opbrengsten en kosten
Hoe Eurofins Scientific geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 6,724 | 326 | 133 | 0 |
| 31 Mar 24 | 6,619 | 291 | 134 | 0 |
| 31 Dec 23 | 6,515 | 257 | 136 | 0 |
| 30 Sep 23 | 6,512 | 335 | 132 | 0 |
| 30 Jun 23 | 6,510 | 414 | 128 | 0 |
| 31 Mar 23 | 6,611 | 497 | 128 | 0 |
| 31 Dec 22 | 6,712 | 581 | 128 | 0 |
| 30 Sep 22 | 6,785 | 612 | 123 | 0 |
| 30 Jun 22 | 6,857 | 643 | 117 | 0 |
| 31 Mar 22 | 6,787 | 696 | 116 | 0 |
| 31 Dec 21 | 6,718 | 749 | 115 | 0 |
| 30 Sep 21 | 6,553 | 786 | 117 | 0 |
| 30 Jun 21 | 6,388 | 824 | 118 | 0 |
| 31 Mar 21 | 5,913 | 665 | 119 | 0 |
| 31 Dec 20 | 5,439 | 505 | 119 | 0 |
| 30 Sep 20 | 5,079 | 347 | 120 | 0 |
| 30 Jun 20 | 4,719 | 190 | 120 | 0 |
| 31 Mar 20 | 4,641 | 168 | 119 | 0 |
| 31 Dec 19 | 4,563 | 146 | 117 | 0 |
| 30 Sep 19 | 4,384 | 144 | 111 | 0 |
| 30 Jun 19 | 4,205 | 143 | 106 | 0 |
| 31 Mar 19 | 3,993 | 159 | 98 | 0 |
| 31 Dec 18 | 3,781 | 175 | 90 | 0 |
| 30 Sep 18 | 3,549 | 182 | 82 | 0 |
| 30 Jun 18 | 3,318 | 190 | 75 | 0 |
| 31 Mar 18 | 3,145 | 185 | 62 | 0 |
| 31 Dec 17 | 2,971 | 179 | 48 | 0 |
| 30 Sep 17 | 2,848 | 166 | 42 | 0 |
| 30 Jun 17 | 2,725 | 152 | 35 | 0 |
| 31 Mar 17 | 2,631 | 145 | 37 | 0 |
| 31 Dec 16 | 2,537 | 138 | 38 | 0 |
| 30 Sep 16 | 2,427 | 104 | 35 | 0 |
| 30 Jun 16 | 2,317 | 69 | 32 | 0 |
| 31 Mar 16 | 2,133 | 63 | 31 | 0 |
| 31 Dec 15 | 1,950 | 56 | 30 | 0 |
| 30 Sep 15 | 1,779 | 71 | 27 | 0 |
| 30 Jun 15 | 1,609 | 86 | 24 | 0 |
| 31 Mar 15 | 1,509 | 82 | 20 | 0 |
| 31 Dec 14 | 1,410 | 78 | 15 | 0 |
| 30 Sep 14 | 1,355 | 66 | 17 | 0 |
| 30 Jun 14 | 1,299 | 53 | 19 | 0 |
| 31 Mar 14 | 1,262 | 53 | 15 | 0 |
| 31 Dec 13 | 1,226 | 53 | 12 | 0 |
Kwaliteitswinsten: ERF has a large one-off loss of €184.8M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: ERF's current net profit margins (4.8%) are lower than last year (6.4%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ERF's earnings have grown by 8.2% per year over the past 5 years.
Versnelling van de groei: ERF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: ERF had negative earnings growth (-21.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-9.9%).
Rendement op eigen vermogen
Hoge ROE: ERF's Return on Equity (7.1%) is considered low.